We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

841% more capital invested

Capital invested by funds: $65.5M → $616M (+$550M)

173% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $3.78M

156% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 18

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

57% more funds holding

Funds holding: 49 → 77 (+28)

Holders
77
Holders Change
+28
Holders Change %
+57.14%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
17
Reduced
8
Closed
18
Calls
$10.3M
Puts
$3.78M
Net Calls
+$6.52M
Net Calls Change
+$1.49M

Top Buyers

1
QF
QVT Financial
New York
+$328M
2
RCM
RA Capital Management
Massachusetts
+$55.6M
3
AWG
Alpha Wave Global
New York
+$45.5M
4
BRC
Blue Ridge Capital
New York
+$34.8M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$33.3M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$6.22M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.95M
3
OSAM
O'Shaughnessy Asset Management
Connecticut
-$1.89M
4
NCCM
Nine Chapters Capital Management
New Jersey
-$1.11M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAA
76
Managed Account Advisors
New Jersey
$1K +$778 +38 +422%
OSAM
77
O'Shaughnessy Asset Management
Connecticut
– -$1.89M -124,853 Closed
Susquehanna International Group
78
Susquehanna International Group
Pennsylvania
– -$1.95M -95,301 Closed
NCCM
79
Nine Chapters Capital Management
New Jersey
– -$1.11M -73,400 Closed
IGIM
80
I.G. Investment Management
Manitoba, Canada
– -$976K -63,750 Closed
Renaissance Technologies
81
Renaissance Technologies
New York
– -$408K -26,700 Closed
Group One Trading
82
Group One Trading
Illinois
– -$541K -26,397 Closed
HSBC Holdings
83
HSBC Holdings
United Kingdom
– -$303K -20,000 Closed
Swiss National Bank
84
Swiss National Bank
Switzerland
– -$259K -16,900 Closed
KPF
85
K2 Principal Fund
Ontario, Canada
– -$261K -12,735 Closed
Nomura Holdings
86
Nomura Holdings
Japan
– -$155K -10,268 Closed
OAM
87
Orinda Asset Management
California
– -$148K -9,759 Closed
GT
88
Glenmede Trust
Pennsylvania
– -$122K -8,000 Closed
SAM
89
Shell Asset Management
Netherlands
– -$85K -4,769 Closed
PCM
90
Prelude Capital Management
New York
– -$46K -3,000 Closed
NPC
91
National Planning Corporation
California
– -$33.5K -2,250 Closed
Northwestern Mutual Wealth Management
92
Northwestern Mutual Wealth Management
Wisconsin
– -$11K -750 Closed
BRWA
93
B. Riley Wealth Advisors
Florida
– -$6 -400 Closed
TDC
94
Thompson Davis & Co
Virginia
– -$2K -125 Closed
BIM
95
BlackRock Investment Management
Delaware
– +$328 +16 New
1 2 3
4

ABUS Hedge Fund Activity: Q1 2015 in Review

77 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2015, worth a combined $616M — up 841% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ABUS positions and 18 closed out — a net gain of 28 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was QVT Financial, opening a new position worth an estimated $328M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.22M.

  • 77 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2015, up from 49 in Q4 2014.
  • Funds reported $616M of Arbutus Biopharma stock for Q1 2015, up 841% quarter-over-quarter.
  • 46 funds opened new Arbutus Biopharma positions in Q1 2015 and 18 closed out, a net change of +28 holders.
  • The largest Arbutus Biopharma buyer in Q1 2015 was QVT Financial, an estimated $328M added.
  • The largest Arbutus Biopharma seller in Q1 2015 was Baker Bros. Advisors, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2015.